About

Janssen is the result of the merger of two pharmaceutical research companies, Janssen Pharmaceutical and Cilag, both groups belonging to the Johnson & Johnson group of companies. In 2010, the company’s Peruvian legal team worked on the merger of Colombia, Peru and Ecuador operations to form the LA Norte Cluster, supporting more than 200 employees. As a result, the cluster has a focus on five specialised lines of work, these being cardiovascular and metabolism, vaccines and infectious diseases, immunology, neurosciences and oncology. The legal team has been at the forefront of the company’s mission to secure compliance and regulatory alignment with pharmaceutical sector, in order to contribute to the improvement of quality of life of many people across Peru and launch innovative treatments for medical needs of many. Most recently the legal team worked on a collaboration and license agreement with US biotech firm Locus Biosciences, in order to develop and manufacture enhanced bacteriophage products targeting two key bacterial pathogens for the treatment of infections of the respiratory tract.